Nebenwirkungen · Kadcyla
Kadcyla 100 mg powder for concentrate for solution for infusion Kadcyla 160 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-125657 · Präparat HOS-096111
Hypersensitivity reactions Hypersensitivity was reported in 2.6% of patients in MBC clinical studies with trastuzumab emtansine, with one Grade 3 and one Grade 4 events reported. Hypersensitivity was reported in 2.7% of patients with EBC, with Grade 3 in 0.4% of patients and no events of higher grade. Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved upon treatment. For dose modifications in the event of hypersensitivity reactions, see sections 4.2 and 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-16T10:48:00Z · SHA-256 5f39c8c258f5d481831223647435155eac55229f855fa7a5be78809b9685324b · Passage 59600d9b71c471cadc4153316332d303fbea0e382698de12f1b253762d2c60e2 · Zeichen 10585–11095 im Abschnitt